daromun

A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), and fibromun (L19-TNFalpha), an immunocytokine consisting of human tumor necrosis factor alpha (TNFalpha) fused to a human scFv antibody fragment directed against the ED-B of L19, with potential antineoplastic and immunostimulating activities. Upon administration, the L-19 moieties of each immunocytokine bind to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 and TNF-alpha moieties of darleukin and fibromun, respectively, may locally induce an immune response against ED-B fibronectin-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.